Equities
Health CarePharmaceuticals & Biotechnology
  • Price (DKK)291.70
  • Today's Change12.70 / 4.55%
  • Shares traded389.57k
  • 1 Year change1.71%
  • Beta0.9532
Data delayed at least 15 minutes, as of Jan 29 2020 14:40 GMT.
More ▼

Profile data is unavailable for this security.

About the company

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

  • Revenue in DKK (TTM)16.81bn
  • Net income in DKK3.09bn
  • Incorporated1950
  • Employees5.57k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LUN:CPH since
announced
Transaction
value
Abide Therapeutics IncDeal completed06 May 201906 May 2019Deal completed1.67%400.00m
Data delayed at least 15 minutes, as of Jan 29 2020 14:40 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
MorphoSys AG531.76m-717.74m27.92bn405.00--8.36--52.50-3.04-3.042.2513.990.127112.664.51216,295.10-17.15-7.94-18.72-8.6795.14---134.97-48.057.79--0.0891--14.45-0.392419.55---15.02--
Evotec SE3.19bn459.54m29.03bn2.76k62.308.3437.929.100.41320.41322.863.090.460331.646.49163,068.406.637.068.299.5429.7931.0414.4114.072.9714.330.48660.0042.3334.30258.54--39.95--
Idorsia Ltd422.38m-3.21bn29.78bn636.00--13.06--70.49-3.51-3.510.46222.490.0457--15.81---34.75---37.36-------760.78------0.6436---61.65---2,607.90------
Swedish Orphan Biovitrum AB (publ)8.42bn1.79bn37.90bn1.28k20.253.3614.224.508.848.8441.4553.340.48632.116.8313,224,940.0010.358.7813.2411.1375.2269.6421.2815.600.923618.060.36640.0040.3633.24110.50--7.10--
Ipsen SA18.80bn3.03bn40.62bn5.72k13.322.729.782.164.874.9430.1623.850.62132.464.94439,664.509.9810.5015.0514.2681.1379.2916.0613.730.613444.120.362329.2416.7312.8743.5222.3035.724.56
Hikma Pharmaceuticals Plc14.44bn2.45bn41.66bn8.41k17.043.3413.022.881.141.146.745.820.61281.833.51194,350.8010.390.594315.080.80252.1653.2216.951.020.845911.710.2737518.677.238.75131.615.8713.1313.12
argenx SE402.19m-749.22m41.99bn105.00------104.40-2.69-2.691.46--------512,590.50---16.05---18.23-----186.28-170.29---------41.0151.66-137.36--60.11--
Orion Corp (finland)7.76bn1.56bn45.70bn3.24k29.178.5523.415.891.491.487.395.071.031.816.07329,359.5020.6820.7426.5926.3660.9360.2320.1221.211.8598.670.011492.04-5.43-0.5909-9.90-0.8685-1.843.71
DiaSorin SpA-747.27bn-747.27bn48.29bn1.95k--------------------------15.48--18.05--68.02--21.12------35.104.979.0013.0513.7510.4610.35
Qiagen NV10.28bn-172.49m53.78bn5.20k--3.1639.065.23-0.1164-0.11645.959.890.29043.204.45277,825.60-0.48722.17-0.60262.3865.4165.39-1.687.232.185.620.4166--5.952.901,032.9622.484.90--
H. Lundbeck A/S16.81bn3.09bn55.56bn5.57k17.943.8612.993.3015.5515.5584.5972.280.73291.844.423,268,715.0013.481.7220.092.5680.4573.9418.392.401.12--0.0458235.625.123.4948.8935.51-14.2134.07
Croda International Plc12.36bn2.08bn58.69bn4.58k28.547.7022.244.751.811.8110.756.690.75033.105.78305,414.8012.6114.4315.3017.5936.9435.9816.8116.490.931428.380.438282.111.015.193.926.0717.535.43
Eurofins Scientific SE31.43bn2.31bn64.41bn42.55k28.533.2013.102.0516.937.89229.90150.710.617153.155.1295,974.535.235.947.107.7319.3618.798.489.340.74236.930.564216.6527.2525.2717.0625.7429.6319.14
BioMerieux SA18.88bn1.97bn79.60bn11.09k40.555.1623.664.222.222.2221.3417.450.74882.595.37227,798.807.716.469.898.5154.5351.9710.298.781.0612.390.240221.765.828.807.819.3311.550.9808
Vifor Pharma AG12.20bn694.01m80.75bn2.76k116.723.8728.566.621.531.5326.8546.030.40632.473.39648,333.304.936.336.119.1058.0734.0612.1311.361.5329.990.168165.5522.68-13.95346.92-12.4430.987.39
Data as of Jan 29 2020. Currency figures normalised to H Lundbeck A/S's reporting currency: Danish Krone DKK

Institutional shareholders

7.03%Per cent of shares held by top holders
HolderShares% Held
Invesco Advisers, Inc.as of 30 Sep 20194.12m2.07%
Norges Bank Investment Managementas of 31 Dec 20182.54m1.27%
The Vanguard Group, Inc.as of 31 Dec 20191.71m0.86%
BlackRock Fund Advisorsas of 09 Jan 20201.48m0.74%
APG Asset Management NVas of 31 Mar 2019881.34k0.44%
Dimensional Fund Advisors LPas of 23 Jan 2020828.83k0.42%
Xact Kapitalf�rvaltning ABas of 31 Dec 2019649.07k0.33%
SEB Investment Management ABas of 31 Dec 2019627.19k0.32%
Nordea Investment Management AB (Denmark)as of 31 Oct 2019598.34k0.30%
Bessemer Investment Management LLCas of 31 Oct 2019568.88k0.29%
More ▼
Data from 31 Dec 2018 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.